Post-Transplantation B Cell Activating Factor and B Cell Recovery before Onset of Chronic Graft-versus-Host Disease

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 5, 2014, Pages 668-675

  Jacobson, Caron A ^a   Sun, Lixian ^a   Kim, Haesook T ^a   McDonough, Sean M ^a   Reynolds, Carol G ^a   Schowalter, Michael ^a   Koreth, John ^a   Cutler, Corey S ^a   Ho, Vincent T ^a   Alyea, Edwin P ^a   Armand, Philippe ^a   Blazar, Bruce R ^b   Soiffer, Robert J ^a   Antin, Joseph H ^a   Ritz, Jerome ^a   Sarantopoulos, Stefanie ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

B cell; B cell activating factor; Chronic graft versus host disease

Indexed keywords

B CELL ACTIVATING FACTOR; BIOLOGICAL MARKER; BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; MYELOABLATIVE AGENT; TNFSF13B PROTEIN, HUMAN;

ADULT; AGED; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; B CELL ACTIVATING FACTOR BETA CELL RATIO; B LYMPHOCYTE; B LYMPHOCYTE RECOVERY; BLOOD CELL COUNT; BONE MARROW HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CHEMOPROPHYLAXIS; CHRONIC GRAFT VERSUS HOST DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; DRUG DOSE TITRATION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; IMMUNOPATHOLOGY; LYMPHOCYTE FUNCTION; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; POSTOPERATIVE PERIOD; PROSPECTIVE STUDY; REDUCED INTENSITY CONDITIONING; WHOLE BODY RADIATION; ADOLESCENT; ALLOTRANSPLANTATION; CHRONIC DISEASE; GENE EXPRESSION; GENETICS; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE COUNT; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROCEDURES; SURVIVAL;

ADOLESCENT; ADULT; AGED; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; CHRONIC DISEASE; FEMALE; GENE EXPRESSION; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84897960209     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.01.021     Document Type: Article

References (42)

1. Gorelik L., Gilbride K., Dobles M., et al. Normal B cell homeostasis requires B cell activation factor production by radiation-resistant cells. JExp Med 2003, 198:937-945.
2. Rickert R.C., Jellusova J., Miletic A.V. Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease. Immunol Rev 2011, 244:115-133.
3. Scapini P., Hu Y., Chu C.L., et al. Myeloid cells, BAFF, and IFN-gamma establish an inflammatory loop that exacerbates autoimmunity in Lyn-deficient mice. JExp Med 2010, 207:1757-1773.
4. Kreuzaler M., Rauch M., Salzer U., et al. Soluble BAFF levels inversely correlate with peripheral B cell numbers and the expression of BAFF receptors. JImmunol 2012, 188:497-503.
5. Manzi S., Sanchez-Guerrero J., Merrill J.T., et al. Effects of belimumab, a Blymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis 2012, 71:1833-1838.
6. Hahn B.H. Belimumab for systemic lupus erythematosus. NEngl J Med 2013, 368:1528-1535.
7. Rodriguez B., Valdez H., Freimuth W., et al. Plasma levels of B-lymphocyte stimulator increase with HIV disease progression. AIDS 2003, 17:1983-1985.
8. Sarantopoulos S., Stevenson K.E., Kim H.T., et al. Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease. Blood 2011, 117:2275-2283.
9. Khan W.N. Bcell receptor and BAFF receptor signaling regulation of Bcell homeostasis. JImmunol 2009, 183:3561-3567.
10. Fedoriw Y., Samulski T.D., Deal A.M., et al. Bone marrow B cell precursor number after allogeneic stem cell transplantation and GVHD development. Biol Blood Marrow Transplant 2012, 18:968-973.
11. Storek J., Witherspoon R.P., Webb D., Storb R. Lack of B cells precursors in marrow transplant recipients with chronic graft-versus-host disease. Am J Hematol 1996, 52:82-89.
12. Storek J., Ferrara S., Ku N., et al. Bcell reconstitution after human bone marrow transplantation: recapitulation of ontogeny?. Bone Marrow Transplant 1993, 12:387-398.
13. Sarantopoulos S., Stevenson K.E., Kim H.T., et al. Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood 2009, 113:3865-3874.
14. Fujii H., Cuvelier G., She K., et al. Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group. Blood 2008, 111:3276-3285.
15. Levine J.E., Paczesny S., Sarantopoulos S. Clinical applications for biomarkers of acute and chronic graft-versus-host disease. Biol Blood Marrow Transplant 2012, 18:S116-S124.
16. Nardelli B., Belvedere O., Roschke V., et al. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 2001, 97:198-204.
17. Moore P.A., Belvedere O., Orr A., et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999, 285:260-263.
18. Scapini P., Carletto A., Nardelli B., et al. Proinflammatory mediators elicitsecretion of the intracellular B-lymphocyte stimulator pool (BLyS) that is stored in activated neutrophils: implications for inflammatory diseases. Blood 2005, 105:830-837.
19. Kanda J., Chiou L.W., Szabolcs P., et al. Immune recovery in adult patients after myeloablative dual umbilical cord blood, matched sibling, and matched unrelated donor hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012, 18:1664-1676.
20. Jacobson C.A., Turki A.T., McDonough S.M., et al. Immune reconstitution after double umbilical cord blood stem cell transplantation: comparison with unrelated peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2012, 18:565-574.
21. Chronic graft-versus-host disease 2004, Cambridge University Press, New York. S. Lee (Ed.).
22. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease, I: Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 2005, 11:945-956.
23. Levine J.E., Uberti J.P., Ayash L., et al. Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy. Biol Blood Marrow Transplant 2003, 9:189-197.
24. Perez-Simon J.A., Diez-Campelo M., Martino R., et al. Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation. Br J Haematol 2005, 130:394-403.
25. Kim D.H., Sohn S.K., Baek J.H., et al. Retrospective multicenter study ofallogeneic peripheral blood stem cell transplantation followed byreduced-intensity conditioning or conventional myeloablative regimen. Acta Haematol 2005, 113:220-227.
26. Turner B.E., Kambouris M.E., Sinfield L., et al. Reduced-intensity conditioning for allogeneic hematopoietic stem-cell transplant determines the kinetics of acute graft-versus-host disease. Transplantation 2008, 86:968-976.
27. Shi-Xia X., Hai-Qin X., Xian-Hua T., et al. Comparison of reduced-intensity and myeloablative conditioning regimens for stem cell transplantation in patients with malignancies: a meta-analysis. Clin Transplant 2011, 25:E187-E198.
28. Nolte M.A., Arens R., van Os R., et al. Immune activation modulates hematopoiesis through interactions between CD27 and CD70. Nat Immunol 2005, 6:412-418.
29. Nilsson A., de Milito A., Mowafi F., et al. Expression of CD27-CD70 onearly B cell progenitors in the bone marrow: implication for diagnosis and therapy of childhood ALL. Exp Hematol 2005, 33:1500-1507.
30. Allen J.L., Fore M.S., Wooten J., et al. Bcells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways. Blood 2012, 120:2529-2536.
31. Sarantopoulos S., Stevenson K.E., Kim H.T., et al. High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. Clin Cancer Res 2007, 13:6107-6114.
32. Thien M., Phan T.G., Gardam S., et al. Excess BAFF rescues self-reactive Bcells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004, 20:785-798.
33. Lesley R., Xu Y., Kalled S.L., et al. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 2004, 20:441-453.
34. Cho B.S., Min C.K., Kim H.J., et al. High levels of B cell activating factor during the peritransplantation period are associated with a reduced incidence of acute graft-versus-host disease following myeloablative allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2010, 16:629-638.
35. Kuzmina Z., Greinix H.T., Weigl R., et al. Significant differences in B-cellsubpopulations characterize patients with chronic graft-versus-hostdisease-associated dysgammaglobulinemia. Blood 2011, 117:2265-2274.
36. Cutler C, Kim HT, Bindra B, et al. Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial. Blood 2013, 122:1510-1517.
37. Cutler C., Antin J.H. Sirolimus immunosuppression for graft-versus-host disease prophylaxis and therapy: an update. Curr Opin Hematol 2010, 17:500-504.
38. Cutler C, Logan BR, Nakamura R, etal. Tacrolimus/sirolimus vs tacrolimus/methotrexate for graft-vs-host disease prophylaxis after HLA-matched related donor hematopoietic stem cell transplantation: results of Blood and Marrow Transplant Clinical Trials Network Trial 0402. Available from: Accessed November 2012. https://ash.confex.com/ash/2012/webprogram/Paper47941.html.
39. Zhang S., Readinger J.A., DuBois W., et al. Constitutive reductions in mTOR alter cell size, immune cell development, and antibody production. Blood 2011, 117:1228-1238.
40. Weichhart T., Haidinger M., Katholnig K., et al. Inhibition of mTOR blocks the anti-inflammatory effects of glucocorticoids in myeloid immune cells. Blood 2011, 117:4273-4283.
41. Heidt S., Roelen D.L., Eijsink C., et al. Effects of immunosuppressive drugs on purified human B cells: evidence supporting the use of MMF and rapamycin. Transplantation 2008, 86:1292-1300.
42. Limon JJ, Fruman DA Akt and mTOR in B Cell Activation and Differentiation. Frontiers in immunology 2012, 3:228.